《基立福Grifols 2024年綜合及可持續發展年度報告「NYSE」（英文版）（262頁）.pdf》由會員分享，可在線閱讀，更多相關《基立福Grifols 2024年綜合及可持續發展年度報告「NYSE」（英文版）（262頁）.pdf（262頁珍藏版）》請在三個皮匠報告上搜索。

1、INTEGRATED ANNUAL REPORT 2024INTEGRATED ANNUAL REPORT2024Introduction3Letter from the CEO4Highlights6Milestones in 20247Sustainability Statement8General9Environment28Social87Governance180Sustainable growth 211Financial Performance212Grifols value creation221Taxation224Annexes228Indices of content ac

2、cording to regulations229Indices of content according to voluntary indices241Methodologies251NON-GAAP measures reconciliation255Glossary and abbreviations257Independent Review Report260Index123Integrated Annual Report 20244IntroductionSustainability StatementSustainable growthAnnexesLetter from the

3、CEOIn a year of overcoming challenges,marked by our conviction in our companys project,I am pleased to report on Grifols strong financial results,key operational and strategic milestones,as well as sustainability achievements in 2024.As I approach my one-year anniversary,I could not be prouder and g

4、rateful to lead a company with the clear mission to improve the lives of patients around the world.Being part of a dedicated team that is as outstanding as the plasma-based medicines and solutions we produce is truly inspiring.Throughout the year,we have maintained our unwavering commitment to susta

5、inable growth,innovation,sustainability and long-term value creation.In 2024,we achieved record revenues of Euros 7.2 billion,a 10%increase over the prior year.This result reflects our success in operating in a market with high growth potential and meeting the robust global demand for plasma protein

6、s,in particular with our immunoglobulin franchise.Numerous milestones point the way for Grifols continued sustainable growth.Operational transformation across our plasma operationsIn 2024 we took further steps to strengthen Grifols competitiveness.We continued to optimize our network of more than 40

7、0 plasma donation centers,achieving a significant reduction in costs and improving the donor experience through more agile and efficient processes.Additionally,we continued to integrate advanced technologies aimed at maximizing yields,increasing productivity and improving operational efficiency.We w

8、ork to integrate these efficiencies into our global and diversified network of centers.Our footprint extends to the United States,Europe,Canada,and Egypt.In this regard,we continue to strive to promote the self-sufficiency of plasma-derived therapies and improve access to our medicines.Commercial st

9、rategy and expansionOur product portfolio continued to grow.The United States Food and Drug Administration(FDA)approved an expanded label for Xembify for the treatment of patients with primary immunodeficiency who have not previously been treated with immunoglobulin.The FDA also approved our plasma-

10、protein based fibrin sealant(FS)for use in controlling surgical bleeding for pediatric patients.We launched Yimmugo,a novel immunoglobulin developed by Biotest,which is expected to generate sales of USD 1 billion over the next seven years,and partnered with Haier for exclusive distribution of albumi

11、n in China for 10 years,with a potential extension to 2044.In Diagnostics,we launched our Erytra Eflexis blood grouping analyzer in China and received European approval for the first in-vitro test to simultaneously detect dengue,Zika,chikungunya and West Nile virus.To ensure production capacity,we o

12、pened a new immunoglobulin purification and filling facility in Clayton,North Carolina.Letter from the CEO of Grifols,Nacho Abia“An exceptional year 2024 marked by teamwork,solid performance,and strategic execution,with the vocation to serve thousands of patients.Integrated Annual Report 20245Introd

13、uctionSustainability StatementSustainable growthAnnexesLetter from the CEOMajor advances in innovationWe continued to make significant progress in 2024 in the development of innovative products.AdFirst,a Phase 3 study investigating the use of fibrinogen to reduce blood loss in critical surgery,demon

14、strated efficacy and safety,while other clinical studies,such as the Phase 1 trial of GIGA-2339,an innovative hepatitis B treatment,continued to advance.We are increasingly incorporating artificial intelligence(AI)into our research capabilities to identify new therapeutic targets.In addition,we have

15、 implemented new solutions to analyze clinical data and optimize plasma donation management to improve process efficiency.These advances in the use of new and cutting-edge technologies reflect our ongoing commitment to research,innovation and the well-being of patients worldwide.Reinforcing our gove

16、rnance practicesTo comply with corporate governance best practices and maximize value for our shareholders,we took a decisive step in 2024 by separating the management and ownership of the company,while remaining faithful to the founding values and commitments that have guided Grifols since its ince

17、ption.Additionally,we have welcomed new members to our Board of Directors,who have brought valuable experience from various key industries.It is a pleasure to have them with us,and we are confident that their contribution,combined with the already strong foundation of our Board,will be essential for

18、 the execution of Grifols strategy.Sustainability as a core pillarIn 2024 Grifols was once again recognized as one of the worlds most sustainable companies ranked number one biotech company in the Dow Jones Best-in-Class Indices.During the year,we strengthened our commitment to sustainability by fur

19、ther integrating environmental,social and governance(ESG)criteria into our strategy and objectives.As part of this commitment,we are enhancing the measurement and reporting of our sustainability performance,to be reflected in our 2025-2027 Sustainability Master Plan,as part of out 2030 Agenda.In the

20、 pages that make up this report,you will find detailed information about our performance during this period.Finally,I would like to thank our shareholders,collaborators,donors,and patients for their continued support and trust.Together,we continue creating value.Sincerely,Nacho AbiaCEO,GrifolsIntegr

21、ated Annual Report 20246IntroductionSustainability StatementSustainable growthAnnexesHighlightsHighlightsInputGenerated valueDonors930,000+390+plasma centersPeople23,822*57%women97 nationalities ResourcesEUR 382 M net R&D investmentEUR 232 M CAPEX InnovationRobust ecosystem6 therapeutic areas Govern

22、anceNew lidership6 independent board members out of 1331%women board members PlanetEUR 44.2 M environmental investment1.1 M m3 water consumption*901 M kWh energy consumption44.6%renewable energy0%coal or nuclear energy consumptionPatients800,000+treatedUSD 29,825 M generated value*7.5 times quality

23、of life improvement*17,000+patients with access to free products or servicesEUR 18.6 M in product donations EUR 9.1 M supporting patient associations People98%permanent contracts5.8+M training hours96.5%workforce trained68.2%women trained3.8%employees with disabilitiesResourcesEUR 7,212 M revenueEUR

24、 1,631 M EBITDAEUR 749 M total tax contributionPlanet3%reduction in the intensity of CO2e emissions in scopes 1,2,325%less scope 2 emissions 47.5%recovered waste37%water treated before discharge*Includes Grifols and Biotest*Water consumption has been calculated as the difference between water extrac

25、tion and water discharge according to international standards.*Calculated with SROI methodology*Biopharma business unitIntegrated Annual Report 20247IntroductionSustainability StatementSustainable growthAnnexesMilestonesMilestones 2024Changes in Grifols governance to separate ownership from manageme

26、nt As part of its strategic plan,on February 5,2024 Grifols announces changes to its corporate governance to separate executive responsibilities from ownership roles.Appointment of new top-tier leaders Nacho Abia assumes the role of Chief Executive Officer on April 1,and Thomas Glanzmann is appointe

27、d non-executive Chairman of the Board on September 23.Additional appointments in the 2024 fiscal year include a new Chief Financial Officer,Chief Human Resources Officer,and President of the Biopharma unit.Majority support from Grifols shareholders in critical moments On June 14,2024,shareholders ap

28、prove all resolutions proposed at the General Shareholders Meeting.Grifols boosts its organic growth Grifols strengthens its immunoglobulin franchise with new indications for XEMBIFY(subcutaneous immunoglobulin)in the United States.In addition,Biotest receives FDA approval for Yimmugo as a treatment

29、 for primary immunodeficiencies.The company closes a strategic alliance with Haier GroupGrifols completes the sale of 20%of its stake in SRAAS and enters a strategic partnership with Haier Group in June.The accord includes an exclusive distribution agreement for albumin over the next 10 years,with t

30、he option to extend it until 2044.Sustainability distinctionsGrifols is recognized as the leading biotechnology company in the Dow Jones Sustainability Index,and is awarded the Gold Medal by EcoVadis for Sustainability Excellence.Additionally,the SBTi approves its short-term science-based emission r

31、eduction targets.Grifols meets its planned innovation objectivesGrifols reports positive results from the phase 4 study of its factor VIII to treat von Willebrand disease;makes important contributions to control surgical bleeding in pediatric patients with its fibrin sealant;and forms a partnership

32、with the U.S.BARDA agency to evaluate its ocular immunoglobulin for treating eye injuries.Financial strengthGrifols concludes its balance sheet optimization by refinancing approximately EUR 4,000 million in debt.As part of this process,Grifols repays nearly EUR 1,600 million of securitized debt,comb

33、ined with the issuance of two secured bonds totaling EUR 2,600 million,maturing in 2030,and the refinancing and extension of its revolving credit facility until 2027.Sustainability Statement19 General28 Environment87 Social180 GovernanceIntegrated Annual Report 20249IntroductionSustainability Statem

34、entSustainable growthAnnexesGeneral l Understanding Grifols9GeneralUnderstanding Grifols-SBM-110Business model10Value chain 13Sustainability strategy and approach15Our stakeholders-SBM-219Double materiality -SBM-3.IRO1/221About this report-BP-1/2.GOV-1/525General basis for preparation of this report

35、.scope and limitations25Governance,risk management and internal control on sustainability disclosures and statement on due diligence26Additional information27Integrated Annual Report 202410IntroductionSustainability StatementSustainable growthAnnexesGeneral l Understanding GrifolsUnderstanding Grifo

36、lsBusiness model Grifols Group(henceforth“Grifols”)is a global healthcare company dedicated to improving peoples health through the innovation,development,production and commercialization of essential plasma-derived medicines,non-plasma therapies and diagnostic solutions.Today,Grifols stands as a gl

37、obal leader in plasma therapies and transfusion medicine.Grifols business model includes four business units:Plasma Procurement and Biopharma1,Diagnostic,Bio Supplies and Other.Each offers specific products and services,ensuring a diversified approach to healthcare,a positive impact on patients and

38、optimal solutions for healthcare professionals.Business units We make a difference for thousands of people Grifols business model places people at the heart of its operations,with a focus on patient health and the well-being of Plasma donors whose generosity make plasma-derived medicines possible.Gr

39、ifols serves as the bridge between Plasma donors and patients.In 2022,Grifols finalized its strategic investment in Biotest AG.Since then,both companies have collaborated closely to expand access to plasma therapies for the benefit of patients worldwide.Grifols is dedicated to enhancing the health a

40、nd well-being of people around the world.Since 1909,we have been at the forefront of innovation,advancing plasma science and diagnostic solutions to contribute to social progress.PURPOSEEnhance global health to help people live longer and healthier livesAMBITIONAmplify our positive impact to advance

41、 our sustainable business modelPLASMA PROCUREMENT AND BIOPHARMAPlasma procurement,production and commercialization of plasma and non-plasma solutions85%over revenues(EUR 6,143 M)DIAGNOSTICLeading-edge diagnostic solutions for blood and plasma analyses9%over revenues(EUR 645 M)BIO SUPPLIESHigh-qualit

42、y biological products for non-therapeutic use3%over revenues(EUR 216 M)OTHERSSpecialty pharmaceuticals and hospital management solutions3%over revenues(EUR 209 M)Total income 2024 EUR 7,212 M 6 Therapeutic areasIMMUNOLOGY AND NEUROLOGYImmunodeficiencies and autoimmune disordersPULMONOLOGYAlpha-1 ant

43、itrypsin deficiency HEMATOLOGYHemophilia and other bleeding and clotting disordersHEPATOLOGY AND INTENSIVE CAREHypovolemia and hypoalbuminemia in liver diseases,cardiac surgery,severe infection and other conditionsJoining forces with BiotestIMMUNOLOGY AND NEUROLOGYHEMATOLOGYHEPATOLOGY ANDINTENSIVE C

44、AREINNOVATIONPlasma and non-plasma therapiesDiagnostic solutions Transfusional and Clinical1.The Plasma Procurement and Biopharma business unit is equivalent to the Biopharma segment described in Note 5 of the consolidated annual accounts.For more information on Grifols Business Units see Integrated

45、 Annual Report 202411IntroductionSustainability StatementSustainable growthAnnexesGeneral l Understanding GrifolsNorth AmericaMemphisMontrealEmeryvilleSan CarlosLos AngelesSan DiegoVistaRaleigh-DurhamClaytonResearch Triangle ParkNORTH CAROLINA HUBCALIFORNIA HUBGlobal footprint and reach ClaytonEmery

46、villeLos AngelesSan DiegoMemphisMontrealVistaNorth Carolina HubResearch Triangle ParkHub CaliforniaSan CarlosLos AngelesSan DiegoEmeryvilleU.S.298Canada 3ClaytonLos AngelesMontrealRaleigh-DurhamEmeryvilleRaleigh-DurhamSan DiegoMemphisVistaCorporate HeadquartersIndustrial FacilitiesR&D CentersBiophar

47、ma CentersDiagnostic CentersBio Supplies CentersOthers CentersPlasma Donor CentersIntegrated Annual Report 202412IntroductionSustainability StatementSustainable growthAnnexesGeneral l Understanding GrifolsEurope HUBBarcelonaBilbaoZaragozaSan SebastinMurciaDublinDdingenLeipzigDreieichMelbourneEuropeB

48、arcelona Germany 62 Hungary 19 Czech Republic 14 Austria 3 BarcelonaBilbaoDublinDdingenDreieichLeipzigMurciaSan Sebastin Hub EuropeDublinBarcelonaBilbaoZaragozaDdingenDreieichBarcelonaDublinDreieichBarcelona Ddingen Leipzig BarcelonaMurciaSan SebastinBilbao Melbourne Melbourne ChinaRoWIntegrated Ann

49、ual Report 202413IntroductionSustainability StatementSustainable growthAnnexesGeneral l Understanding GrifolsValue chain The production of plasma-derived medicines,driven by the Plasma Procurement and Biopharma business units,lies at the core of Grifols operations.These areas are further supported b

50、y the Diagnostic and Bio Supplies business units,which enhance and optimize the companys value chain.Grifols stands out for its rigorous management of the value chain,grounded in ethical principles,quality and sustainability that exceed regulatory requirements.The company promotes a sustainable and

51、responsible value chain,continuously incorporating due diligence policies and procedures.This approach promotes managerial excellence and helps prevent or mitigate negative impacts,both real and potential,on human rights and the environment.In parallel,it also helps minimize risks and capitalize on

52、surrounding opportunities.To this end,Grifols integrates environmental,social and governance(ESG)principles throughout its value chain.The company is committed to ensuring the highest standards of quality and safety in its products and services,building trust and loyalty among patients,plasma donors

53、 and the healthcare community.Plasma donors Plasma donation centers Production plantsDescription:Donors are an essential part of Grifols value chain,specialized in plasma-derived medicines.Role:They provide the raw material necessary to produce plasma-derived medicines.Description:Grifols operates a

54、 broad network of plamsa donation centers.Role:They safely collect,process and store plasa in compliance with strict norms and regulations.Description:Grifols has state-of-the-art installations for the fractionation of plasma and purification of plasma proteins.Role:They transform plasma into specif

55、ic medicines including immunoglobulins,albumins,alpha-1 and clotting factors.Regulatory bodiesResearch and development centers(R+D)Distributors and sales forceDescription:Government organisms and internatinal agencies such as the FDA,EMA and other local authoritiesRole:They guarantee processes and p

56、roducts comply with safety and quality norms.Description:Grifols invests in innovation through in-house R+D and its investees.Role:They develop new therapies and diagnostic solutions,while improving existing processes.Description:Companies and entities that distribute Grifols products globally.Role:

57、They facilitate the delivery of products to hospitals and healthcare centers.Logistics and transportEnd clientsConsumers and patientsDescription:Companies in charge of transporting plasma and finished products under controled conditions.Role:They guarantee that products arrive on time and in optimal

58、 conditions.Description:Hospitals,healthcare centers,healthcare professionals and patients.Role:They use specific treatments,especially in areas such as hemotology,immunology and intensive care,among others.Description:Patients who need specific plasma-derived therapies.Role:They are at the heart of

59、 Grifols activity.More details on resource inputs(raw materials)in the value chain and resource outputs(end products):“Circular Economy”in the“Environment”chapter.More details on supplier management and relations:“Governance”chapterMAIN ACTORS AND ASSETS IN GRIFOLS VALUE CHAIN Integrated Annual Repo

60、rt 202414IntroductionSustainability StatementSustainable growthAnnexesGeneral l Understanding Grifols930,000+qualified donors390+donation centersPLASMA FROM DEDICATED DONORSANALYSIS OF DONATED PLASMABroad portfolio of transfusion-medicine productsMANUFACTURE OF MEDICINES Only suitable plasma is used

61、 in production Elimination of pathogens at every manufacturing stage 3 main stages:protein separation or fractionation,purification and asceptic fillingUnsuitable plasma is sold via BIO SUPPLIES5 essential plasma therapiesCOMMERCIALIZATION:SERVING HEALTHCARE PROFESSIONALS800,000+patients treated eve

62、ry yearHolographic seal and vials with unique codes prevent counterfeitingIn-house development and commercialization via DIAGNOSTICProduction and commercialization of plasma-derived medicines via BIOPHARMA10+analysesof highly sensitive NAT and ELISA techniquesPATIENT FOLLOW-UPProduct tracking and tr

63、aceabilityPlasma collection via PLASMA PROCUREMENTServing as a bridge between patients and donors60%ALBUMIN21%ALPHA+BETA GLOBULINS15%IMMUNO-GLOBULINS3%FIBROGEN1%CLOTTING FACTORSPATIENTS WHO IMPROVE THEIR QUALITY OF LIFEDONORIntegrated Annual Report 202415IntroductionSustainability StatementSustainab

64、le growthAnnexesGeneral l Understanding GrifolsSustainability strategy and approach Sustainability as a strategyGrifols is committed to sustainability,with a dual focus on economic growth and a staunch commitment to social and environmental responsibility.The company recognizes the inseparable conne

65、ction between the environment and human health,understanding the impact of pollution,climate change,biodiversity loss,ecosystem degradation and other factors on living conditions and peoples physical and mental well-being.From Grifols perspective,this integration not only promotes a more sustainable

66、 future but also enhances the organizations long-term value by reinforcing its resilience and adaptability in a dynamic global market.In this regard,Grifols has made significant progress in recent years,while remaining focused on embedding sustainability across all its business functions and units t

67、hrough a holistic,cross-cutting approach.The progress achieved and commitments made in 2024 are detailed in this report.As a worldwide leader in plasma-derived medicines,Grifols centers its strategy on ensuring a sustainable plasma supply through an extensive global network of donation centers,while

68、 continually optimizing its production processes.Its diversified portfolio includes both plasma and non-plasma therapies,along with diagnostic and hospital solutions that complement its core business and extend its reach.Grifols drives global growth through strategic acquisitions,market expansion an

69、d key alliances.Its unwavering commitment to innovation is evident in its continuous development of new therapies and advanced technologies,supported by high-potential subsidiaries such as Biotest AG,GigaGen Inc.and Alkahest Inc.,among others.This innovative approach further reinforces its industry

70、leadership.At the same time,the company strives to fortify a robust financial strategy that promotes growth and maximizes shareholder value.With over 115 years of history and a legacy of four generations dedicated to serving society,Grifols continues to advance as a global benchmark in the healthcar

71、e sector.PRIORITIES OF GRIFOLS MANAGEMENT TEAM PlasmaGuarantee plasma supply and access to treatmentsPromote a diversified network of plasma centers and maximize their efficiencyInnovationPrioritize critical innovation projectsFocus on differentiated products through in-house and investee-led initia

72、tivesIntegrate innovation and digital transformation projects that streamline processes and add value to the business modelPlasma donors and patientsGreater commitment to patients,healthcare professionals and plasma donorsTalentFoster leadershipPromote a culture based on talent recognition and conti

73、nuous developmentAdvocate and promote diversity,inclusion and equal opportunityPromote employee health and well-beingFinancial performanceReduce debtFinancial discipline and cost controlSustainable growthNew business models and expansionPromote public-private collaborations to increase countries sel

74、f-sufficiency in plasma-derived medicinesEstablish strategic alliances in high-potential marketsSustainabilityContinue to build an organization-wide culture of sustainabilityMaintain a robust sustainability strategy and roadmapIncrease the integration of ESG analyses and evaluations in decision-maki

75、ng frameworksIntegrated Annual Report 202416IntroductionSustainability StatementSustainable growthAnnexesGeneral l Understanding GrifolsOur roadmap:Sustainability Master Plan Grifols approach to integrating sustainability is outlined in the Sustainability Policy and Sustainability Master Plan,which

76、forms part of the companys Strategic Plan and aligns with the United Nations Sustainable Development Goals(SDGs).In 2024,the company began updating its Sustainability Master Plan for 2025-2027,considering the impacts,risks and opportunities identified through the double materiality analysis;new ESG-

77、related regulatory requirements;emerging market and societal expectations concerning global sustainability;and its corporate strategy.With this revision,the company will enhance its ability to anticipate emerging risks,comply with regulatory and societal expectations,and solidify its role as a susta

78、inability leader to ensure a positive long-term impact.Overview of corporate policies:“Governance”chapter.Access to:Grifols Sustainability Policy;Master Plan;and 2030 AgendaOUR SUSTAINABILITY MASTER PLAN IS GROUNDED ON 6 PILLARSMAIN PILLARS CARING ABOUT OUR PEOPLE COMMITTING TO SOCIETYOur Aim:employ

79、ees feel they are part of a company that promotes diversity,continuous development,equal opportunities,gender equality and that strives to improve well-being at the workplaceOur Aim:healthier and wealthier society,by positively contributing to social progress,supporting organizations and actively pa

80、rticipating in local communities FOSTERING HEALTH EMBRACING NATUREOur Aim:solid community where every donor feels valued for its commitment and understands its impact beyond compensation,and every patient receives the treatment it requiresOur Aim:advance towards the common good of having healthy pla

81、ces to live,work and play,by raising awareness on the need to protect the planetTRANSVERSAL PILLARS ENCOURAGING ETHICAL PRACTICES FOSTERING INNOVATIONOur Aim:placing human rights at the core of our practices and having the highest ethical standards integrated throughout the supply chainOur Aim:scien

82、tific progress addressing the needs of our patients,lead by our pioneering spirit and protecting the rights,safety and well-being of clinical trial participantsIntegrated Annual Report 202417IntroductionSustainability StatementSustainable growthAnnexesGeneral l Understanding GrifolsObjectives with a

83、 clear timeline:Grifols Agenda 2030In 2021,as part of its sustainability strategy,Grifols established 30 corporate goals aligned with the SDGs:the Grifols 2030 Agenda.In 2022,the company once again ratified its commitments,setting intermediate targets to be achieved by 2024,as detailed below:Environ

84、mental responsibility Intermediate milestones 202455%decline in GHG emissions per unit of production-15%415%increase in energy efficiency per unit of production+5%4100%electricity consumed from renewable sources 27%4Promote decarbonization in business travel and work commutes Same target 20304Increa

85、se circular economy measures at each stage of the operational life cycle Same target 20304Protect biodiversity in the companys natural areas to capture CO2 Same target 20304Our people Impart 100 hours of training hours/year/personSame target 20304Deliver annual training to 70-80%of the workforceSame

86、 target 20304Increase percentage of women in Senior Manager roles to 50%41%4Increase percentage of people with disabilities to 3-5%of total employee poolSame target 20304Ensure women comprise 50%of interviews for managerial positions45%4Maintain employee turnover rate below industry average*Same tar

87、get 20304Achieve 70%overall employee engagement rate per department63%475%increase in installations certified as healthy workplaces54%NA15%decrease in LTIFR(lost time injury frequency rate)5.3%475%of installations with ISO 45001 certification54%In processCommitment to plasma donors and patientsAchie

88、ve EUR18 million per year in donations to support patient programs13 M EUR/yearIn processIncrease donations of clotting factors to 240 million IU90M UI4Achieve 90%approval among donors for positive customer service(good or excellent rating)Same target 2030NAAttain 80%referral rate from active donors

89、Same target 20304Increase ratings via the Donor Hub by 45%Same target 2030NASocial impactIncrease the number of social outreach initiatives and investments by 50%35%+(initiatives)13%+(social investment)In processAllocation of 25%of social initiatives for STEM scholarships for women20%In processReach

90、 USD1 million in donations of products and medicines for emergency relief efforts750 k USD4Increase funds for Jos Antonio Grifols i Lucas Foundation by 10%10%4Increase by 10%the amount allocated to bioethics grants and by 20%number of activities developed by Vctor Grifols i Lucas Foundation10%4Ethic

91、al commitment 2030Implement ESG criteria among suppliers up to 60-80%of total spending volume25%4Maintain Biopharma claims ratio in 1/50,000 Same target 20304Maintain For more details,please refer to the document“Management of risks and opportunities related to climate change”*For more details,pleas

92、e refer to the Report on the Human Rights Due Diligence Process More information:“Stakeholders”section.3.Assessment of identified impacts,risks and opportunities(IROs)The materiality of the previously identified IROs is assessed in this phase in line with the criteria defined in ESRS 1-General Requi

93、rements of the CSRD.The indicators applied differ depending on whether the assessment focuses on impacts or on risks and opportunities.In either case,the values for each indicatorsuch as probability or severityare determined by considering both the aforementioned internal and external information.Th

94、e risk assessment is carried out using the following indicators as a base:The likelihood of the impacts occurrence(where 10%is very unlikely and 90%is very likely).The assessment does not consider current impacts as they are already occurring.In accordance with best practices,this indicator is not e

95、valuated for human rights-related impacts in order to give greater weight to severity.The severity of impacts takes into account:Scale:analyzes the seriousness or benefit of each impact(where 1 is very unlikely and 5 is very serious/beneficial).Scope:examines the extension of the impact in terms of

96、the number of people affected or the magnitude of the environmental damage(where 1 is an impact on a specific sector and 5 represents extensive impact).Irremediability:evaluates the degree of difficulty involved in counteracting or correcting the resultant damage(where 1 requires short and quick act

97、ion,and 5 represents an irremediable impact).This variable does not apply in the case of positive impacts.The assessment of risks and opportunities is carried out using the ERM2 Risk Assessment Model and includes:Likelihood of occurrence Potential magnitude of the financial effects of each risk and

98、opportunity(where 1 is very little and 5 is high).The analysis of the financial impact was conducted considering qualitative criteria and factors.2.Enterprise Risk Management More information on risk management and control:“Governance”chapter.,More information on the ERM Risk Assessment Model:“Risk

99、Management and control”chapter.4.Stakeholder engagementFor Grifols,incorporating the interests and views of its stakeholders into its business strategy is essential.To this end,their integration in its identification and assessment processes is also key.Stakeholder interests and views are considered

100、 from three perspectives:Continuous dialogue:Given the importance of stakeholder communication,Grifols maintains ongoing communication with all relevant groups,as outlined in the“Stakeholders”section.Specific actions:In addition to maintaining continuous dialogue,Grifols spearheaded a series of init

101、iatives in 2024 to gain a deeper understanding of its stakeholders needs and interests.These included:Workshops for Grifols employees in Spain Employee interviews in the United States Surveys for plasma donors Meetings with Grifols employees who hold relevant positions or have expertise in the topic

102、s under analysis,including the Environment,Corporate Affairs,Human Resources,Global Procurement,Enterprise Risk Management and Internal Audit departments.Integrated Annual Report 202423IntroductionSustainability StatementSustainable growthAnnexesGeneral l Double materiality Consultation of documenta

103、tion from independent experts:Stakeholder viewpoints were integrated by analyzing reports and communications from a range of representative organizations,including plasma donors,patients,employees,public health systems,foundations,NGOs and local communities.The following organizations and documents

104、were reviewed:Core provisions of the International Labour Organization(ILO)Donor and patient resources from the Plasma Protein Therapeutics Association(PPTA)Public information disclosed by the World Health Organization(WHO)on national health systems,with a focus on the U.S.and Europe Public disclosu

105、res by the World Federation of Hemophilia Public disclosures by the American Liver Foundation Public information from the International Patient Organisation for Primary Immunodeficiencies(IPOPI)Public information on the sectors contribution to sustainability from international analysts(MSCI,S&P Glob

106、al,etc.)Media impact analysis on communication outlets,with an emphasis on the local communities where Grifols operates Results from Grifols most recent global employee survey 5.Validation of results at the highest level of the organization.The final results of the analysis were presented and approv

107、ed by the Sustainability Committee,Appointments and Remunerations Committee and Grifols Board of Directors of Grifols.Results of the double materiality analysisEach CSRD(Corporate Sustainability Reporting Directive)topic and sub-topic encompasses the impacts,risks,and opportunities that are material

108、 to Grifols activity.These material topics and sub-topics can be identified based on the IROs that define each area.Information on the material IROs of each sub-topic:consult specific chapterGrifols double materiality matrix in 2024EnvironmentalE11Climate change adaptation2Climate change mitigation3

109、EnergyE24Pollution of air5Pollution of water6Pollution of soil7Pollution of living organisms and food resources8Substances of concern9Substances of very high concern10MicroplasticsE311Water12Marine resourcesE413Direct impact drivers of biodiversity loss14Impacts on the state of species15Impacts on t

110、he extent and condition of ecosystems16Impacts and dependencies on ecosystem servicesE517Resources inflows,including resource use18Resource outflows related to products and services19WasteSocialS120Working conditions21Equal treatment and opportunities for all22Other work-related rightsS223Working co

111、nditions24Equal treatment and opportunities for all25Other work-related rightsS326Communities economic,social and cultural rights27Communities civil and political rights28Rights of indigenous peoplesS429Information-related impacts30Personal safety31Social inclusion of consumersGovernmentalG132Corpor

112、ate culture33Protection of whistle-blowers34Animal welfare35Political engagement36Management of relationships with suppliers including payment practices37Corruption and briberyEntity specificOther38Innovation39CybersecurityImpact materialityFinancial materialityImpact MaterialNon MaterialDouble Mate

113、rialFinancial Material137467891012131415162728181921222324252933343523511172026303132363839Integrated Annual Report 202424IntroductionSustainability StatementSustainable growthAnnexesGeneral l Double materialityGRIFOLS PRIORITY MATERIAL ISSUESTopicPatients and healthcare professionals(S4)Climate cha

114、nge(E1)Plasma donors and donor communities(S3)Sub-topicsImpacts related to information(29)Personal safety(30)Social inclusion of consumers(31)Adaptation to climate change(1)Mitigation of climate change(2)Energy(3)Communities economic,social and cultural rightsMaterial IROs*Responsible and transparen

115、t business conduct(I+)(SP)Improvement in patients well-being(I+)(SP)Quality and safety of products and services(I-)(R)Intensification of health policies and other regulations(R)Access to treatments and diagnostics(I+-)(R)More sustainable healthcare systems(I+)(OO)Increase in extreme weather events(R

116、)Contribution to climate change through GHG emissions from scopes 1,2,and 3(I-)(OO)(SP)Non-compliance with climate goals or legal requirements(R)Non-renewable energy consumption(I+-)(OO)Insufficient energy supply(R)Health and well-being of plasma donors and their communities(I+-)(OO)(SP)(R)Contribut

117、ion to communities local and social development(I+)(OO)(SP)Why is it material?Grifols,through its products,has a profound impact on patients lives.The companys ability to provide safe,effective and accessible treatments is crucial to public health.Climate change presents a challenge with far-reachin

118、g implications for Grifols.At the same time,the company can potentially make a significant contribution to mitigating climate change mitigation through improvements in operational efficiency,the adoption of renewable energy,and the development of sustainable products and processes.Grifols operates i

119、n a complex and dynamic environment characterized by significant risks and opportunities linked to the availability of plasma and the well-being of donor communities.Impact on the company Grifols commitment to patient health and the satisfaction of healthcare professionals is essential for its long-

120、term growth and sustainability.Product quality and safety-related risks,as well as those arising from potential regulatory changes,must be carefully managed to mitigate any potential financial impacts.Grifols can contribute to a more sustainable future by integrating sustainability into its core bus

121、iness strategy.Nevertheless,climate change also presents significant risks to Grifols operations.Extreme weather events and emissions-related regulatory changes may impact its financial performance and operational resilience.Grifols has the potential to generate significant positive impacts by creat

122、ing jobs and contributing to public health through its life-saving therapies.At the same time,plasma shortages and risks to plasma donors health pose threats to the companys operations.By proactively addressing these challenges,Grifols can help ensure the long-term sustainability of its business.Bus

123、iness strategyThe management of the impacts,risks and opportunities of Grifols activities on patients and healthcare professionals is outlined in“Patients and Healthcare Professionals.”This section includes a description of the policies and actions implemented to promote patient well-being,ensure ac

124、cess to treatments and other initiatives undertaken in this regard.The management of the impacts,risks and opportunities related to climate change is outlined in the“Climate Change”section,which includes a description of the policies and actions established to address this topic.*The management of t

125、he impacts,risks and opportunities related to this topic is outlined in the“Donors and Donor Communities”section,which includes a description of the policies and actions established to ensure the health of plasma donors and advance community development.Integration in risk managementThe risks identi

126、fied regarding this material topic are fully integrated into the companys ESG risk management system.For more details,see“Patients and Healthcare Professionals”section.The risks relating to climate change are fully integrated into the companys risk management system.The identified risks and the acti

127、ons designed for their mitigation are developed further in the“Climate Change”section.*The risks identified regarding this material topic are fully integrated into the companys ESG risk management system.These risks are further developed in the“Donors and Donor Communities”section.Performance metric

128、(2030 objective)Biopharma claims ratio(maintain below 1/50,000)Number of critical deficiencies identified by external authorities(maintain below 1)Financial donations to support patient programs(EUR 18M/year)*Clotting factor donations through the FMH agreement(240M IU)*Product and medicine donations

129、 for emergency relief through Direct Relief(USD 1M)*Absolute scope 1 and 2 GHG emissions(42%reduction compared to 2022.Science-based target)*Absolute scope 3 GHG emissions(25%reduction compared to 2022.Science-based target)*GHG scope 1 and 2 emissions per unit of production(55%reduction compared to

130、2018)*Energy efficiency per unit of production(15%increase compared to 2018)*Electricity consumption from renewable sources(100%)*These objectives and targets are also incorporated in Grifols three-year corporate environmental program.*Number of social initiatives and their investment(50%increase co

131、mpared to 2020 and 2021,respectively)Percentage of social initiatives dedicated to STEM scholarships for women(25%)Resources allocated to the Jos Antonio Grifols Lucas Foundation(10%increase compared to 2020)Resources dedicated to scholarships and activities carried out by the Vctor Grfols i Lucas F

132、oundation(10%and 20%increase,respectively,compared to 2020)Executive variable compensationAmong other factors,executive variable compensation is subject to financial and non-financial metrics and parameters,including a specific metric linked to the achievement of ESG objectives.In 2024,10%of the var

133、iable compensation is tied to ESG factors,with 25%related to environmental,40%to social and 35%to governance factors.*More information:See“Impacts,risks and opportunities”in the sections dedicated to each material issue.*The impact of climate change on Grifols and its management is specifically addr

134、essed in the“Risk and Opportunities Management Related to Climate Change”report.*Objectives integrated in Grifols 2030 Agenda.For more information on its progress and milestones,see“Grifols 2030 Agenda”in“Understanding Grifols.”*Objectives approved by the SBTi initiative.For more information,consult

135、 the section“Objectives to reduce emissions approved by the SBTi in the“Environment”chapter.*More information:see“Climate change mitigation under the 2023-2026 Environmental Program”in“Environment”.*For more information,please refer to the Board of directors remuneration policy,Annual Corporate Gove

136、rnance Report and Directors Remuneration Report in ;also see“ESG criteria in long-term compensation”section of this report.+Positive impact -Negative impact R Risk OO Own Operation SP Supply ChainIntegrated Annual Report 202425IntroductionSustainability StatementSustainable growthAnnexesGeneral l Ab

137、out this reportThis report has considered the requirements of Directive 2022/2464/EU(CSRD1),taking as a reference the set of standards,principles,and criteria related to sustainability information established in the European Sustainability Reporting Standards(ESRS)and other requirements applicable t

138、o the entity originating from Spanish legislation and directly applicable European regulations,including the requirements on Taxonomy contemplated in Article 8 of Regulation(EU)2020/852 on taxonomy.(See Annex-Index of disclosure requirements in ESRS covered by the Sustainability statement(ESRS 2 IRO

139、-2).Grifols followed a double materiality approach in this report,considering the opinion of its main stakeholders and adhering to the new CSRD requirements.Furthermore,this report has been prepared in accordance with the GRI Standards:Core option(see Annex-GRI Content Index).Likewise,SASB standards

140、 related to the“Biotechnology and Pharmaceuticals”sector have been included(see Annex-SASB Index).Additionally,this report demonstrates Grifols commitment to its contribution to the Sustainable Development Goals.The annex“Index of SDGs and Global Compact principles to which Grifols contributes”conta

141、ins the list of SDGs to which contributions are made,as well as a detail of the outstanding contributions made in the 2024 fiscal year.Given the companys formal adherence to the United Nations Global Compact,Grifols complies through this document with the reporting of the updated Communication on Pr

142、ogress(COP).This report includes a description of the practical actions the company has taken and plans to take to implement the Global Compact Principles in each of the four thematic areas(human rights,labor,environment,and anti-corruption).All measurable results are well described in each of the c

143、hapters of this report.Perimeter and scope of the reportThis report covers the period from January 1 to December 31,2024,corresponding to Grifols fiscal year.For the purposes of this report,Grifols S.A.and all its subsidiaries are considered as“Grifols2”.The reported information includes all depende

144、nt companies with a stake greater than 51%or under control according to the IFRS definition as reflected in the Consolidated Financial Statements.About this report General basis for preparation of this report.scope and limitations Biotek America LLC,a joint operation between Grifols and Immunotek GH

145、 LLC,has not been included in the scope of this report due to the Groups lack of sufficient non-financial and sustainability information regarding this entity.As of December 31,2024,this company operates 14 plasma centers3.The Group will take the necessary steps to include information on the locatio

146、ns(14 plasma centers)of Biotek America LLC in the report to be prepared following its planned acquisition during 2025(see Notes 10 and 34 of the consolidated financial statements).In relation to the Non-controlled entities by Grifols,S.A.-Grifols Egypt for Plasma Derivatives(S.A.E.),Medcom Advance,S

147、.A.,BioDarou PLC and Shanghai RAAS Blood Products Co.Ltd.have been considered in the calculation of the environmental footprint.Except as indicated above,this report covers Grifols main business units4:Plasma Procurement and Biopharma5,Diagnostic,Bio Supplies and Others,which together account for 10

148、0%of the groups turnover.These business units integrate all the key operations of the groups value chain,from procurement(including plasma collection)and manufacturing,to affiliates.Regarding value chain operations for which information was not available and could not be estimated,Grifols has applie

149、d the three-year moratorium provided for in the Transitional Provision of Article 5 of the CSRD Directive,which allows companies a period of adaptation before fully implementing the new reporting requirements.Grifols believes that this report provides a fair and balanced view of the companys economi

150、c,environmental,and social performance.While there are certain exceptions to the scope,as detailed above,these do not materially impact the consolidated indicators and therefore should not affect the readers assessment of the companys performance.For a comprehensive understanding of the information

151、in this report,please consider the following additional points.“Environment”chapterThe data provided in this section represents Grifols total production and commercial activities with the exception of commercial subsidiaries with fewer than 10 employees.Since most of Grifols manufacturing facilities

152、 are located in the United States and Spain,the environmental information included in this section is classified by division and region as U.S.,Spain and rest of the world(RoW).3.The 14 plasma centers of Biotek America LLC represent 3.39%of the total number of plasma centers owned by the Group as of

153、 December 31,2024.4.For more details on Grifols main business units,please refer to the section“Understanding Grifols”.5.The Plasma Procurement and Biopharma business unit corresponds to the Biopharma segment as described in Note 5 of the consolidated financial statements.1.This regulation complemen

154、ts Directive 2013/34/EU regarding the disclosure requirements on sustainability information.2.A list of Grifols subsidiaries can be found in Appendix I of the Consolidated Annual Accounts for the fiscal year ended December 31,2024.Integrated Annual Report 202426IntroductionSustainability StatementSu

155、stainable growthAnnexesGeneral l About this report“Social”chapterGrifols included figures for the last two years classified by gender(female,male,non-binary and not declared),age and region(U.S.,Europe and RoW)in all cases where historical figures were available.Europe includes Austria,Czech Republi

156、c,France,Germany,Ireland,Italy,Poland,Portugal,Spain,Sweden,Switzerland and the United Kingdom.The scope of the indicators related to remuneration includes the workforce in the United States,Spain,Germany and Ireland.The data provided by Grifols regarding training hours represents 98,1%of the total

157、workforce as of December 31,2024.It includes all companies within the group except for Plasmavita Healthcare,Alkahest Inc,GigaGen Inc,Grifols Inn and New Technologies,and Haema Plasma Kft.Indicators for absenteeism,people with disabilities and accident rates are limited to data from the United State

158、s,Spain,Ireland and Germany.Comparability Regarding comparability,for the data reported on the Biotest group,the performance data of this company,particularly regarding human resources and the environment,is presented in separate tables to allow for comparability with previous years data.Within the

159、tables titled“Grifols”,the following considerations should be taken into account:(1)the 2023 tables include the wholly-owned subsidiaries acquired in 2023:Biotest France SAS,Biotest UK Ltd.,Biotest Italy S.r.l.,Biotest Farmaceutica Ltda.,and Biotest Medical S.L.U.(2)In 2024,the aforementioned compan

160、ies,except for Biotest UK Ltd.,have merged with other Grifols companies.Biotest AG annually publishes a set of management approaches and key policies on .Additionally,in the sections where historical data appear,figures for the last three fiscal years(2022-2024)have been included where available.The

161、 historical data presented in this report have not been recalculated to adjust for changes in perimeter that have occurred in each fiscal year or the application of the CSRD framework.Governance Grifols sustainability governance is led by its Board of Directors.The companys Sustainability Committee,

162、established by the Board,ensures adherence to principles and commitments related to environmental,social and governance responsibilities.The governance processes,controls and procedures established by Grifols to manage,oversee and monitor sustainability matters are outlined in the“Governance”chapter

163、.These include:The roles of management,executive and supervisory bodies Information provided to these bodies and the sustainability matters they address The integration of sustainability performance into incentive systems,which is covered in both the“Governance”and the“Our People”chaptersRisk manage

164、ment and internal controls for sustainability information disclosureGrifols manages the risks and internal controls related to sustainability information disclosure through a comprehensive approach,with an emphasis on transparency,quality,reliability and alignment with internationally recognized sta

165、ndards.In 2022,Grifols introduced a systematized reporting tool that has significantly enhanced the methodological rigor in the collection,support and validation of data.The structure and content of the sustainability report,which includes the Statement of Non-Financial Information and consolidated

166、sustainability information,are reviewed and approved by the Sustainability Committee,the Appointments and Remunerations Committee and the Board of Directors.Core elements of due diligenceSection in the sustainability statementa)Embedding due diligence in governance,strategy and business modelGeneral

167、 Information and Governanceb)Engaging with affected stakeholders in all key steps of the due diligenceGeneral Information,Environment,Social and Governancec)Identifying and assessing adverse impactsGeneral Informationd)Taking actions to address those adverse impactsGeneral Information,Environment,So

168、cial and Governancee)Tracking the effectiveness of these offorts and communicatingGeneral Information,Environment,Social and GovernanceIntegrated Annual Report 202427IntroductionSustainability StatementSustainable growthAnnexesGeneral l About this reportIn terms of environmental reporting,Grifols ha

169、s a standard operating procedure(SOP)which establishes the systematic approach to data collection,in which each user has a defined role:contributors provide the data,approvers validate it and administrators manage the system.In addition,internal audits are carried out to monitor the correct implemen

170、tation of the process,which applies to all Grifols companies worldwide with more than 10 employees in offices,or where the company has more than a 50%shareholding.This procedure has been optimized with the implementation of software designed to collect and manage data in an efficient and structured

171、manner.This system enables the preparation of the 2024 Non-Financial Information Statement and Sustainability reporting,as well as other internal and external reports.In 2025,Grifols is developing its Global Reporting Manual,with the aim of standardizing and improving the reporting process for non-f

172、inancial and sustainability information.This manual will provide clear guidelines to ensure transparency and consistency in the disclosure of environmental,social and governance(ESG)data.Additional information The information contained in this report is complemented by the Corporate Governance Repor

173、t and the Directors Remuneration Report.All these documents,together with the audited accounts,provide a comprehensive and transparent view of the company.Annual Corporate Governance ReportGrifols 2024 Corporate Governance Annual Report is included in the Management Report and is available on both t

174、he CNMV website and Grifols website from the date of publication of the consolidated annual accounts.Annual Directors Remuneration Report Grifols Annual Directors Remuneration Report for 2024 is included in the Directors Report and is available on the CNMV website and Grifols website from the date o

175、f publication of the consolidated annual accounts.Subsequent events and foreseeable evolution of the group For more information on subsequent events after the close of year and the foreseeable evolution of the group,please refer to the management report accompanying the audited consolidated statemen

176、ts for the 2024 fiscal year on Grifols website:.CONTENIDOSEnvironment Environmental management29A cross-cutting and comprehensive approach29The internal regulatory framework-key policies30Certified Environment Management System30Environmental governance31Resources allocated to environmental manageme

177、nt32Key performance indicators of environmental management33EU Taxonomy34Context and main conclusions34Taxonomy Framework35EU Taxonomy Key performance indicators37Climate Change-ESRS E143Impacts,risks and opportunities43Climate Change adaptation47Climate Change mitigation47Energy consumption and ene

178、rgy mix51Key performance indicators of Climate Change54Pollution-ESRS E262Impacts,risks and opportunities62Grifols comprehensive approach to pollution management63Water pollution64Wastewater and discharge management65Key performance indicators of Pollution65Water resources-ESRS E367Impacts,risks and

179、 opportunities67Water is an essential resource for Grifols68Water withdrawal and consumption69Key performance indicators of water70Biodiversity-ESRS E475Grifols biodiversity management75Biodiversity protection and conservation programs76Circular Economy-ESRS E577Impacts,risks and opportunities77Reso

180、urce inflows:raw material consumption80Resource outflows81Waste management82Key performance indicators of Circular Economy83Integrated Annual Report 202429IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Environmental managementGrifols Environmental ManagementEco-efficiency

181、 Integration of environmental criteria into the design of new projects,products and services,and the review of existing ones.R+D departments of ISO 14001-certified companies and Grifols engineering project teams assess the most eco-efficient alternatives for new and existing products and projects,in

182、 line with the companys established procedures and regulatory requirements.Use of Grifols“Guide to Environmentally Responsible Packaging and Container Design”.Prevention Regular reviews of preventive measures to minimize potential environmental risks.Routine emergency and incident drills for environ

183、mental impacts at certified production plants.Targeted environmental training.Regulatory compliance Implementation of legislative monitoring systems and regular compliance reviews in certified companies.Proactive short-and long-term action plans Six environmental commitments outlined in Grifols 2030

184、 Agenda.Commitment to achieving net-zero emissions by 2050(scopes 1 and 2).Short-term emissions reduction targets approved by SBTi in 2024,with a 2030*target.2023-2026 Corporate Environmental Program.Environmental communication and awareness Reinforcing communication channels with key stakeholders.I

185、nternal and external communication protocols.More than 3,600 hours of training,education and awareness activities on environmental management and conservation in 2024,including company-wide guidance on waste management,water use and electricity consumption.*More information on Science Based Targets

186、InitiativeGrifols environmental management framework is focused on climate change,pollution,water resources,biodiversity and the circular economy.The company takes a holistic,integrated approach centered on eco-efficiency and prevention,regulatory compliance and proactive planning for both short-and

187、 long-term sustainability.This strategy is reinforced by a staunch commitment to environmental awareness and transparent communication.To support effective implementation,Grifols established an internal regulatory framework and an ISO 14001-certified environmental management system,applied across it

188、s production facilities.A cross-cutting and comprehensive approachIntegrated Annual Report 202430IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Environmental managementThe internal regulatory framework key policies GLOBAL RISK MANAGEMENT POLICY:Defines the environmental,s

189、ocial and corporate governance(ESG)risks that may impact the organization,including climate change.Environmental risk management is integrated in the companys multidisciplinary risk management process.SUSTAINABILITY POLICY:Establishes the organizations core environmental and social responsibility pr

190、inciples and commitments,and serves as a framework for their full integration into the business model.ENVIRONMENTAL POLICY:Defines company-wide guidelines,principles and commitments in order to monitor and mitigate its environmental impact.CLIMATE ACTION POLICY:Outlines Grifols specific commitments

191、to climate action.ENERGY POLICY:Defines corporate objectives in Grifols Environmental Management System,including eight key commitments to minimize energy demand and promote the use of renewable energies.BIODIVERSITY POLICY:Establishes Grfiols commitments to biodiversity conservation and protection,

192、ensuring a strategy that aligns with broader sustainability objectives across its areas of operation and influence.Certified Environment Management SystemGrifols implements an ISO 14001-certified environmental management system for its main production facilities to identify and comply with all appli

193、cable environmental legislation;recognize the environmental impacts of its processes and products;implement necessary prevention and corrective measures;and establish objectives to boost its environmental performance.This standardized global system includes the corporate environmental manual,which o

194、ffers an organization-wide framework for Grifols environmental management.All certified companies and those in the process of certification have an environmental committee led by their respective senior management team.This is the highest decision-making body responsible for defining environmental g

195、uidelines,ensuring implementation and maintenance of the Environment Management System,including allocating human and financial resources.By the end of 2024,73%of Grifols total production excluding Biotest was manufactured in ISO 14001-certified plants,and 70%of production workers operate in certifi

196、ed facilities.Grifols prioritized the certification process of its largest production plants and is progressively certifying smaller facilities or those with a lower environmental impact.All certified plants undergo audits by the independent certification body TV Rheinland.Additionally,the company e

197、nsures its buildings and facilities are sustainably designed.In 2024,it continued to work toward LEED(Leadership in Energy and Environmental Design)certification for its new production facilities in Montreal,Canada.LEED is the worlds largest scale green building rating system.In 2024 Grifols was awa

198、rded a B-rating by the Carbon Disclosure Project Climate Change.The worlds leading environmental disclosure platform,CDP annually assesses corporate climate strategies and performance.In line with its commitment to transparency with stakeholders,Grifols also participated in the CDP Water Report in 2

199、024.MANAGEMENTSUSTAINABLY DESIGNED AND ECO-EFFICIENT FACILITIESISO 14001ISO 50001LEED CERTIFICATION*GREEN GLOBES*ZERO WASTE TO LANDFILL*SPAINAll manufacturing,engineering,logistics and commercial companiesCorporate headquarters in BarcelonaUSABiopharma facilities in Clayton(NC),Offices in Raleigh(NC

200、),Diagnostic facilities in Emeryville(CA)Clayton(NC)office building Clayton(NC)raw materials warehouseClayton(NC)Purificationand filling plantClayton(NC)fractionation plantClayton(NC)production plantCANADAFractionation plant and albumin New Montreal production plant(under construction to meet LEED r

201、equirements)BIOTESTDreieich(Germany)production facilities*Leadership in Energy and Environmental Design.*Green Globes certified by the Green Building Initiative.*Zero Waste to Landfill,awarded by Underwriters Laboratories(UL).Access ISO 14001 certification and CDP environmental performance results i

202、n Grifols&Environment.All policies are publicly available at Integrated Annual Report 202431IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Environmental managementBoard of DirectorsSustainability Committee Sustainability Steering Committee Corporate Risk CommitteeEnvironm

203、ental Committee Environmental governanceGrifols Board of Directors establishes a range of commitments to minimize environmental and climate risks and oversees their management,in addition to approving the Corporate Risk Policy,Sustainability Policy and other policies related to the environment,clima

204、te action,energy and biodiversity.Given its strategic importance,the Environmental Policy is signed by Grifols CEO.The Executive Committee regularly monitors Grifols environmental performance and public reporting,including key climate-change indicators and actions,as well as financial risk and impac

205、t assessments associated with climate change.The Sustainability Committee,Sustainability Steering Committee and Environment Committee drive and direct the implementation of the environmental objectives defined in Grifols Sustainability Master Plan and environmental programs.The Chief Industrial Serv

206、ices Officer(CISO),a member of the Executive Committee and Environment Committee,reports regularly to the CEO on the status of Grifols environmental performance.The CISO also approves the Energy Policy,environmental program and allocation of economic and human resources to meet established environme

207、ntal objectives.With regard to remuneration policies and performance indicators,the Energy Manager receives incentives tied to the increase in renewable energy procurement through Power Purchase Agreements(PPAs).Finally,the Corporate Risk Committee,which reports to the Board of Directors,develops an

208、d oversees the risk management model,ensuring an integrated approach to managing environmental risks and promoting sustainable business practices.“Grifols robust governance framework oversees the management of environmental impacts,risks and opportunities.PROVISIONS AND GUARANTEES FOR ENVIRONMENTAL

209、RISKSGrifols civil liability insurance policy covers accidental environmental pollution,defined as the disturbance to the natural state of the air,water,soil,flora or fauna(or any other situation classified as environmental pollution under applicable legislation)caused by emissions from its faciliti

210、es as a result of single,sudden and unforeseen events.Grifols liability extends to all its companies,production facilities and offices in all its regions of operation.In 2024,Grifols no environmental-related financial penalties were issued in relation to adverse environmental impact.At Grifols,the c

211、ontrol,prevention and management of environmental risks is articulated through a global strategy.All of the companys ISO 14001-certified facilities operate under an environmental management system to minimize and mitigate environmental risks,including those derived from its operations(anthropogenic

212、activity)and those produced by natural events(natural),such as extreme weather and climate-related phenomena.Each facility has site-specific self-protection plans that define the necessary actions in the event of an environmental emergency and establish the designated teams responsible for their imp

213、lementation.Relevant training is provided for all those involved in environmental risk management in accordance with Grifols continuous development plan.Integrated Annual Report 202432IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Environmental managementCORPORATE DEPARTM

214、ENTSUBSIDIARY COORDINATORSENVIRONMENTAL COMMITTEESENVIROMENTAL TEAMS118114SpainMexico,Brazil,Chile,Poland,Czech Republic,Germany Switzerland,France,United Kingdom,Ireland,Portugal,Italy,Japan,China,Hong Kong,Thailand,Singapore,AustraliaU.S.(3)SpainResource allocation EUR 44.2 M in 2024*EUR 111 M in

215、the last 3 years*Includes costs and investments.Investment in environmental assetsEUR 15.8 M39%eco-efficiency39%water cycle2%waste management20%miscellaneous projects Environmental expensesEUR 28.3 M72%waste managementNORTH AMERICACanada U.S.LATIN AMERICAMexicoColombiaBrazilChileArgentinaEUROPESpain

216、 Poland Czech Republic Germany Switzerland France United Kingdom Ireland Portugal Italy SlovakiaJapanChinaDubaiTaiwanHong KongIndiaThailandSingaporeIndonesiaAustralia Resources allocated to environmental management Grifols allocated significant resources to environmental activities as part of its co

217、mmitment to progressively advance on its 2023-2026 Corporate Environmental Program objectives.In 2024,the total resources allocated to mitigating its environmental impact increased by 35%compared to 2023.Investments more than doubled,following a year of financial restraint,while operating expenses r

218、emained stable.For more information on resources allocated to environmental activities,see the tables at the end of this sectionIndustrial facilitiesIntegrated Annual Report 202433IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Environmental managementEnvironmental managem

219、ent key performance indicatorsENVIRONMENTAL EXPENSES In thousands of euros 202420232022Waste management20,362.0021,290.00 17,544.51 Water cycle7,918.456,660.11 7,893.98 Reducing atmospheric emissions and energy 60.0984.00 57.69 Others0.000.00 290.63 Total 28,340.5428,034.11 25,786.81 ENVIRONMENTAL E

220、XPENSES-BIOTEST In thousands of euros 202420232022Water cycle0.001,594.00 0.00 Reducing atmospheric emissions and energy 287.080.00 795.30 Total 287.081,594.00 795.30 ENVIRONMENTAL INVESTMENTSIn thousands of euros 202420232022Waste management262.57427.11 2,275.40 Water cycle6,246.45518.46 1,263.40 R

221、educing atmospheric emissions and energy 6,157.452,575.37 1,502.60 Others3,149.161,253.39 3,331.00 Total 15,815.634,774.33 8,372.40 ENVIRONMENTAL INVESTMENTS-BIOTESTIn thousands of euros 202420232022Water cycle0.000.00 0.00 Reducing atmospheric emissions and energy 293.001,000.00 0.00 Total 293.004,

222、774.33 0.00 Environmental expenses and investmentsIntegrated Annual Report 202434IntroductionSustainability StatementSustainable growthAnnexesEnvironment l TaxonomyEU taxonomy of environmentally sustainable activities Context and main findings Revenue(Turnover)CapExOpExEligibility in figures(EUR)4,7

223、40,499,195297,944,613144,052,948%Eligibility65.73%62.30%72.15%Alignment in figures(EUR)078,4360%Alignment0%0%0%The Taxonomy Regulation is set out in various delegated regulations2 and annexes that elaborate on the economic activities that can be considered sustainable in relation to the six environm

224、ental objectives mentioned above.And it details the technical criteria that activities must meet to determine their significant contribution to any of the six objectives,as well as the criteria for assessing that the activity do not cause significant harm(DNSH)to any of the other environmental objec

225、tives.In this context,the group has carried out an analysis of its economic activities to determine whether any of them can be considered environmentally sustainable.It has been concluded that,in 2024,the main business activity,the manufacture of medicines,is an eligible,non-aligned activity.Additio

226、nally,several economic activities not directly relating to its main activity were qualified as eligible under the Taxonomy due to their connection with incurred expenses or investments during 2024.1.The Taxonomy Regulation establishes criteria for using figures related turnover,CAPEX,OPEX and turnov

227、er that differ from traditional concepts.For this reason,there may be disparities between the figures used to calculate the Taxonomy compared to those presented elsewhere in Grifols report.2.Delegated Regulation(EU)2021/2178 specifies the content and presentation of the information to be disclosed b

228、y specifying the figures to be considered in relation to CAPEX,OPEX and turnover.In 2020,the European Commission adopted the Taxonomy Regulation(EU)2020/852.This regulation is one of the main actions of the European Unions Sustainable Finance Action Plan(SFAP),which is part of the European Green Dea

229、l.With this plan the European Union seeks to direct investment flows towards activities aligned with sustainable development and to contribute to the transition towards a greener and more sustainable economyThe Taxonomy is a classification system for determining whether an investment or economic act

230、ivity is considered environmentally sustainable.In essence,it seeks to provide a common and transparent framework for companies and investors to assess and report on the environmental impact of their economic activities.Specifically,entities are asked to report on the proportion of the turnover of s

231、uch large non-financial companies,their capital expenditure(hereafter“CapEx”)or their operating expenses(hereafter“OpEx”)associated with environmentally sustainable economic activities1.The Taxonomy covers various economic sectors and activities,setting out specific and detailed criteria for assessi

232、ng their contribution to six environmental objectives:Climate change mitigationClimate change adaptationSustainable use and protection of water and marine resourcesTransition to a circular economyPollution prevention and controlProtection and restoration of biodiversity and ecosystems Integrated Ann

233、ual Report 202435IntroductionSustainability StatementSustainable growthAnnexesEnvironment l TaxonomyLIST OF GRIFOLS ELIGIBLE ACTIVITIES FOR 2024TargetActivityBrief description according to the RegulationBrief description according to Grifols activitySustainable use and protection of water and marine

234、 resources2.2 Urban waste water treatmentThe operation of urban wastewater infrastructure,including treatment plants,sewer networks,storm water management structures,connections to wastewater infrastructure,decentralized wastewater treatment facilities,as well as treated effluent discharge structure

235、sThe Biopharma business units main production plants,located in Barcelona(Spain)and Clayton(North Carolina,USA),have on-site wastewater treatment plants to reduce COD before discharge to the public sewer.For more information see:Water pollution.Pollution prevention and control1.2.Manufacture of medi

236、cinal productsManufacture of medicinal products.Grifols core business,which consists of producing plasma-derived medicines and other solutions.Protection and restoration of biodiversity and ecosystems1.1.Conservation,including the recovery of habitats,ecosystems and speciesInitiation,development and

237、 implementation,either independently or on commission or by contract,of conservation activities,including restoration activities to maintain or improve the conditions and trends of land,freshwater and marine habitats,ecosystems,and their related flora and fauna populations.Grifols owns more than 120

238、 hectares of protected forest in Clayton,North Carolina(U.S.)located near its production complex.More information:“Biodiversity protection and conservation programs.”Methodology of Analysis First phase:eligibility analysisTo determine eligibility,the analysis focused on identifying economic activiti

239、es contributing to key performance indicators(KPIs)turnover,CapEx,and OpEx that align with the activities specified in the Climate Delegated Act(2021/2139)and its amendments(2023/2485).The main activity,manufacture of medicines,is described in the Taxonomy regulation.Specifically,it consists of acti

240、vity 1.2.Manufacture of medicinal products,which falls under the environmental objective of Pollution prevention and control.Additionally,other secondary economic activities of the company have been identified that are not directly related to its core business but are related to investments(CapEx)or

241、 expenditures(OpEx)made in 2024 and are therefore also considered eligible under the Taxonomy.Second phase:alignment analysisIn accordance with the Taxonomy Regulation for the fiscal year 2024,the alignment of those activities that can contribute to one of the 6 objectives has been assessed.This ass

242、essment has been carried out taking into account the three conditions that an economic activity must meet to be considered environmentally sustainable:Substantially contribute to at least one of the 6 objectives defined by the Taxonomy(EU Regulation 2020/852 Arts.10 to 16)Do no significant harm to o

243、ther objectives(EU Regulation 2020/852 Art.17)Comply with minimum social safeguards(EU Regulation 2020/852 Art.18)As a result of the alignment analysis,it has been concluded that Grifols main activity is not aligned with the Taxonomy,and that it contributes to the objective“Sustainable use and prote

244、ction of water resources”with one of its eligible secondary activities.The main activity,1.2 Manufacture of medicinal products,is not aligned with the Taxonomy,as it does not meet the criterion of Not causing significant harm to the climate change mitigation objective.This is due to the fact that th

245、e production of plasma derivatives requires a multi-stage cold chain that starts with obtaining the raw material,passing through manufacturing and finally storage and dispatch of the finished product.Raw material procurement,transport and storage in Plasma Logistics Centres(PLC)is common to all bloo

246、d products and is carried out at-30C/-35C.Climate change mitigation criteria require that pharmaceutical products requiring refrigeration use a refrigerant gas with a GWP of 150 or lower,this level of GWP can only be achieved with ammonia and/or CO2 based solutions.This is the standard for Grifols n

247、ew facilities in a large part of the cold chain;however,to date,Grifols does not has any product which throughout its cold chain is manufactured 100%,at all stages,using refrigerant gases with a GWP of less than 150.Integrated Annual Report 202436IntroductionSustainability StatementSustainable growt

248、hAnnexesEnvironment l Taxonomy The secondary activity,2.2 Urban wastewater treatment,contributes to the objective;Sustainable use and protection of water resources and is considered environmentally sustainable.The above activity has been determined to be environmentally sustainable as the following

249、points have been verified:1.Compliance with the technical screening criteria for substantial contribution to the objective:Sustainable use and protection of water resources.2.Compliance with the technical screening criteria to do not significant harm(DNSH)to the other environmental objectives,as est

250、ablished by EU Taxonomy for this activity in question.3.Compliance with the Minimum Social Safeguards outlined in Article 18 of the Taxonomy Regulation”and in the“Social”and“Governance”sections of this document.Calculation of economic indicators Calculation of the percentage of turnoverThe calculati

251、on of the turnover ratio,as defined in Article 8(2)(a)of Regulation(EU)2020/852,takes into account the proportion of turnover derived from products or services associated with economic activities deemed environmentally sustainable under the EU Taxonomy(numerator),divided by net turnover(denominator)

252、,as defined in Article 2(5)of Directive 2013/34/EU.Turnover includes income recognized by International Accounting Standard(IAS)1,paragraph 82(a),adopted by Commission Regulation(EC)No.1126/2008.In Grifols case,the numerator includes the sum of turnover(as reflected in the International Financial Re

253、porting Standards adopted by the European Union(IFRSEU)group 70)associated with accounts considered eligible from a taxonomy perspective.With regard to the numerator of the turnover KPI,Grifols has identified as eligible activity 1.2 Manufacture of medicinal products under the objective of Pollution

254、 prevention and control,and has therefore taken into consideration the income related to the manufacturing activities of plasma-derived products and other medicines produced almost entirely by the Plasma Procurement and Biopharma division.In addition,this year the group has further analyzed the comp

255、anies engaged in the manufacture of medicines.As a result of this analysis,the figures corresponding to the economic activities of distribution and marketing of products,which in the 2023 taxonomy report were included in the“Manufacture of medicines”activity,have been excluded from the eligible acti

256、vity 1.2.For this reason,the comparative figures reported in the 2023 taxonomy tables have been restated.The figure in the denominator of the taxonomy tables coincides with the total turnover included in the consolidated profit and loss account of the consolidated annual accounts of the Grifols Grou

257、p3.Calculation of the CapEx percentageAs stipulated in Article 8(2)(b)of Regulation(EU)2020/852,the CAPEX ratio is calculated by dividing the numerator by the denominator,with the denominator representing the additions to tangible and intangible assets during the relevant period before depreciation,

258、amortization and any possible revaluations,including those resulting from revaluations and impairments,corresponding to the relevant period,excluding changes in fair value.The denominator will also include additions to tangible and intangible assets resulting from business combinations.Regarding the

259、 numerator,it consists only of the aggregation of the CapEx of the activities considered eligible from a taxonomic point of view.For the activity of 1.2 Manufacture of medicinal products,the same considerations have been applied as previously explained in the point“Calculation of the percentage of t

260、urnover”.And the denominator corresponds to the total CapEx of the Grifols group,which includes investments in intangible assets,investments in property,plant and equipment and investments in assets for right of use 4.Calculation of the OpEx percentageIn adherence to Article 8(2)(b)of Regulation(EU)

261、2020/852,the OPEX ratio is calculated by dividing the numerator by the denominator.The OPEX denominator includes direct non-capitalized costs related to research and development,building-renovation measures,short-term leases,maintenance and repairs,and other direct expenses linked to the daily maint

262、enance of tangible fixed assets,whether performed by the company itself or by third-party subcontractors,to ensure their continued and effective operation.In this case,for the calculation of the OpEx indicator,the following have been considered:Direct non-capitalized costs associated with research a

263、nd development.Short-term leases that have not been capitalized,Maintenance and repair costs.It should be noted that expenses related to the routine maintenance of tangible fixed assets,such as cleaning services or repairs to computer systems,were excluded from the numerator calculation,in accordanc

264、e with Article 8 of the regulation and the accounting methodology adopted by Grifols for presenting these expenses.In line with the principle of prudence,expense accounts lacking sufficient detail to determine whether they were related to maintenance directly linked to the analyzed taxonomic activit

265、ies,or other types of maintenance,were not considered eligible.Accordingly,the denominator of the indicator encompasses the expenditure composed of the three concepts described above,while the numerator is the expenditure only of the activities that have been recognized as eligible according to the

266、established criteria.For the activity of 1.2 Manufacture of medicinal products,the same considerations have been applied as previously explained in the point“Calculation of the percentage of turnover”.3.The sum of the denominator figure of the turnover tables included in“Results Grifols”and“Results

267、Biotest”coincides with the turnover figure in the consolidated income statement of the consolidated annual accounts of the Grifols group for the year ended 31 December 2024.4.Total Group CapEx(see Appendices III,IV and V attached to the consolidated financial statements)Integrated Annual Report 2024

268、37IntroductionSustainability StatementSustainable growthAnnexesEnvironment l TaxonomyResults of the Taxonomy 2024 analysisThe following tables show the data corresponding to the Turnover,CapEx and OpEx of Grifols corresponding economic activities that comply with the European Taxonomy.Consistent wit

269、h the rest of the Consolidated Statement of Non-Financial Information and Sustainability Information,Grifols presents the taxonomy tables for Grifols and Biotest separately.Grifols ResultsFinancial year 2024Year 2024Substantial Contribution CriteriaDNSH criteria(Does Not Significantly Harm)Economic

270、Activities(1)Code(2)Turnover(3)Proportion of Turnover 2023(4)Climate Change Mitigation(5)Climate Change Adaption(6)Water(7)Pollution(8)Circular Economy(9)Biodiversity(10)Climate Change Mitigation(11)Climate Change Adaption(12)Water(13)Pollution(14)Circular Economy(15)Biodiversity(16)Minimum Safeguar

271、ds(17)Proportion of Taxonomy-aligned(A,1)or-eligible(A.2.)turnover,2023(18)Category enabling activity(19)Category transitional activity(20TextEUR%S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b)(c)S/NS/NS/NS/NS/NS/NS/N%FTA.TAXONOMY-ELIGIBLE ACTIVITIESA.1.Environmenta

272、lly sustainable activities(Taxonomy-aligned)Turnover of environmentally sustainable activities(Taxonomy-aligned)(A.1)00-0%Of which Enabling00-0%FOf which Transitional00-0%TA.2 Taxonomy-Eligible but not environmentally sustainable activities(not Taxonomy-aligned activities)EL,N/EL(f)EL,N/EL(f)EL,N/EL

273、(f)EL,N/EL(f)EL,N/EL(f)EL,N/EL(f)1.2 Manufacture of medicinal productsPPC 1.24,247,003,344.0063.21%N/ELN/ELN/ELELN/ELN/EL68.80%Turnover of Taxonomy-eligible but not environmentally sustainable activities(not Taxonomy-aligned activities)(A.2)4,247,003,344.0063.21%0%0%0%63.21%0%0%68.80%A.Turnover of T

274、axonomy eligible activities(A.1+A.2)4,247,003,344.0063.21%0%0%0%63.21%0%0%68.80%B.TAXONOMY-NON-ELIGIBLE ACTIVITIES Turnover of Taxonomy non-eligible activities2,471,794,187.0036.79%TOTAL6,718,797,531.00100%TURNOVERIntegrated Annual Report 202438IntroductionSustainability StatementSustainable growthA

275、nnexesEnvironment l TaxonomyCAPEXFinancial year 2024Year 2024Substantial Contribution CriteriaDNSH criteria(Does Not Significantly Harm)Economic Activities(1)Code(2)CapEx(3)Proportion o CapEx(4)Climate Change Mitigation(5)Climate Change Adaption(6)Water(7)Pollution(8)Circular Economy(9)Biodiversity(

276、10)Climate Change Mitigation(11)Climate Change Adaption(12)Water(13)Pollution(14)Circular Economy(15)Biodiversity(16)Minimum Safeguards(17)Taxonomy-aligned proportion of CapEx,2023(18)Category enabling activity(19)Category transitional activity(20)TextEUR%S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,

277、N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S/NS/NS/NS/NS/NS/NS/N%FTA.TAXONOMY-ELIGIBLE ACTIVITIESA.1.Environmentally sustainable activities(Taxonomy-aligned)7.4 Installation,maintenance and repair of charging stations for electric vehicles in buildings(and parking spaces attached to buildings)CCM 7.478

278、,436.000.02%N/ELN/ELSN/ELN/ELN/ELSSSSSSS0%CapEx of environmentally sustainable activi-ties(Taxonomy-aligned)(A.1)78,436.000.02%0%0%0.02%0%0%0%SSSSSSS0%Of which Enabling00-0%FOf which Transitional00-0%TA.2 Taxonomy-Eligible but not environmentally sustainable activities(not Taxonomy-aligned activitie

279、s)EL.N/EL(f)EL.N/EL(f)EL.N/EL(f)EL.N/EL(f)EL.N/EL(f)EL;N/EL(f)1.2Manufacture of medicinal productsPPC 1.2262,523,450.7261.94%N/ELN/ELN/ELELN/ELN/EL50.80%CapEx of Taxonomy-eligible but not environmentally sustainable activities(not Taxonomy-aligned activities)(A.2)262,523,450.7261.94%0%0%0%61.94%0%0%

280、50.80%A.CapEx of Taxonomy eligible activities(A.1+A.2)262,601,886.7261.96%0%0%0.02%61.94%0%0%50.80%B.TAXONOMY-NON-ELIGIBLE ACTIVITIESCapEx of Taxonomy non-eligible activities161,193,687.7538.04%TOTAL423,795,574.47100%Proportion of CapEx/Total CapExTaxonomy-aligned per objectiveTaxonomy-eligible per

281、objectiveCCM 0%0%CCA 0%0%WTR 0.02%0%PPC 0%61.94%CE 0%0%BIO 0%0%Integrated Annual Report 202439IntroductionSustainability StatementSustainable growthAnnexesEnvironment l TaxonomyOPEXProportion of OpEx/Total OpExTaxonomy-aligned per objectiveTaxonomy-eligible per objectiveCCM 0%0%CCA 0%0%WTR 0%0%PPC 0

282、%61.96%CE0%0.00%BIO 0%0.03%Financial year 2024Year 2024Substantial Contribution CriteriaDNSH criteria(Does Not Significantly Harm)Economic Activities(1)Code(2)OpEx(3)Proportion of OpEx 2023(4)Climate Change Mitigation(5)Climate Change Adaption(6)Water(7)Pollution(8)Circular Economy(9)Biodiversity(10

283、)Climate Change Mitigation(11)Climate Change Adaption(12)Water(13)Pollution(14)Circular Economy(15)Biodiversity(16)Minimum Safeguards(17)Proportion of Taxonomy-aligned(A,1)or-eligible(A.2.)OpEx,2023(18)Category enabling activity(19)Category transitional activity(20)TextEUR%S,N,N/EL(b)(c)S,N,N/EL(b)(

284、c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S/NS/NS/NS/NS/NS/NS/N%FTA.TAXONOMY-ELIGIBLE ACTIVITIESA.1.Environmentally sustainable activities(Taxonomy-aligned)OpEx of environmentally sustainable activities(Taxonomy-aligned)(A.1)00-0%Of which Enabling00-0%FOf which Transitional00-0%TA.2

285、Taxonomy-Eligible but not environmentally sustainable activities(not Taxonomy-aligned activities)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)1.2 Manufacture of medicinal productsPPC 1.274,620,853.0061.96%N/ELN/ELN/ELN/ELN/ELEL60.96%1.1 Conservation,including restoration,of habitats,e

286、cosystems and speciesBIO 1.131,609.010.03%N/ELN/ELN/ELELN/ELN/EL0.01%OpEx of Taxonomy-eligible but not environmentally sustainable activities(not Taxonomy-aligned activities)(A.2)74,652,462.0161.98%0%0%0%61.96%0%0.03%60.97%A.OpEx of Taxonomy eligible activities(A.1+A.2)*174,652,462.0161.98%0%0%0%61.

287、96%0%0.03%60.97%B.TAXONOMY-NON-ELIGIBLE ACTIVITIES OpEx of Taxonomy non-eligible activities45,785,320.2938.02%TOTAL120,437,782.30100%Integrated Annual Report 202440IntroductionSustainability StatementSustainable growthAnnexesEnvironment l TaxonomyBiotest ResultsFinancial year 2024Year 2024Substantia

288、l Contribution CriteriaDNSH criteria(Does Not Significantly Harm)Economic Activities(1)Code(2)Turnover(3)Proportion of Turnover 2023(4)Climate Change Mitigation(5)Climate Change Adaption(6)Water(7)Pollution(8)Circular Economy(9)Biodiversity(10)Climate Change Mitigation(11)Climate Change Adaption(12)

289、Water(13)Pollution(14)Circular Economy(15)Biodiversity(16)Minimum Safeguards(17)Proportion of Taxonomy-aligned(A,1)or-eligible(A.2.)turnover,2023(18)Category enabling activity(19)Category transitional activity(20TextEUR%S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b)(c)S;N;N/EL(b

290、)(c)S/NS/NS/NS/NS/NS/NS/N%FTA.TAXONOMY-ELIGIBLE ACTIVITIESA.1.Environmentally sustainable activities(Taxonomy-aligned)Turnover of environmentally sustainable activities(Taxonomy-aligned)(A.1)00-0%Of which Enabling00-0%FOf which Transitional00-0%TA.2 Taxonomy-Eligible but not environmentally sustaina

291、ble activities(not Taxonomy-aligned activities)EL,N/EL(f)EL,N/EL(f)EL,N/EL(f)EL,N/EL(f)EL,N/EL(f)EL,N/EL(f)1.2 Manufacture of medicinal productsPPC 1.2493,495,851100%N/ELN/ELN/ELELN/ELN/EL71.28%Turnover of Taxonomy-eligible but not environmentally sustainable activities(not Taxonomy-aligned activiti

292、es)(A.2)493,495,851100%0%0%0%100%0%0%71.28%A.Turnover of Taxonomy eligible activities(A.1+A.2)493,495,851100%0%0%0%100%0%0%71.28%B.TAXONOMY-NON-ELIGIBLE ACTIVITIES Turnover of Taxonomy non-eligible activities-0%TOTAL493,495,851100%TURNOVERProportion of turnover/Total turnoverTaxonomy-aligned per obj

293、ectiveTaxonomy-eligible per objectiveCCM 0%0%CCA 0%0%WTR 0%0%PPC 0%100%CE0%0%BIO 0%0%Integrated Annual Report 202441IntroductionSustainability StatementSustainable growthAnnexesEnvironment l TaxonomyCAPEXFinancial year 2024Year 2024Substantial Contribution CriteriaDNSH criteria(Does Not Significantl

294、y Harm)Economic Activities(1)Code(2)CapEx(3)Proportion o CapEx(4)Climate Change Mitigation(5)Climate Change Adaption(6)Water(7)Pollution(8)Circular Economy(9)Biodiversity(10)Climate Change Mitigation(11)Climate Change Adaption(12)Water(13)Pollution(14)Circular Economy(15)Biodiversity(16)Minimum Safe

295、guards(17)Taxonomy-aligned proportion of CapEx,2023(18)Category enabling activity(19)Category transitional activity(20)TextEUR%S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S/NS/NS/NS/NS/NS/NS/N%FTA.TAXONOMY-ELIGIBLE ACTIVITIESA.1.Environmentally sustainable act

296、ivities(Taxonomy-aligned)CapEx of environmentally sustainable activi-ties(Taxonomy-aligned)(A.1)000%0%0.03%0%0%0%SSSSSSS0%Of which Enabling00-0%FOf which Transitional00-0%TA.2 Taxonomy-Eligible but not environmentally sustainable activities(not Taxonomy-aligned activities)EL.N/EL(f)EL.N/EL(f)EL.N/EL

297、(f)EL.N/EL(f)EL.N/EL(f)EL;N/EL(f)1.2 Manufacture of medicinal products PPC 1.234,042,463.0062.58%N/ELN/ELN/ELELN/ELN/EL59,81%4.1 Electricity generation using solar photovoltaic technology CCM 4.17,793.000.01%ELN/ELN/ELN/ELN/ELN/EL1,35%4.25 Production of heat/cool using waste heatCCM 4.25279,282.150.

298、51%ELN/ELN/ELN/ELN/ELN/EL0,53%6.5 Transport by motorbikes,pas-senger cars and light commercial vehiclesCCM 6.5379,336.350.70%ELN/ELN/ELN/ELN/ELN/EL0,71%6.6 Freight transport services by roadCCM 6.6135,403.840.25%ELN/ELN/ELN/ELN/ELN/EL*7.2 Renovation of existing buildingsCCM 7.223,000.000.04%ELN/ELN/

299、ELN/ELN/ELN/EL*7.5 Installation,maintenance and repair of instruments and devices for measuring,regulation and controlling energy performance of buildingsCCM 7.5156,882.740.29%ELN/ELN/ELN/ELN/ELN/EL0,13%8.1 Data processing,hosting and related activitiesCCM 8.1318,565.000.59%ELN/ELN/ELN/ELN/ELN/EL0,3

300、8%CapEx of Taxonomy-eligible but not environmentally sustainable activities(not Taxonomy-aligned activities)(A.2)35,342,726.0864.97%2%0%0%63%0%0%64,03%A.CapEx of Taxonomy eligible activities(A.1+A.2)35,342,726.0864.97%2%0%0%63%0%0%64,03%B.TAXONOMY-NON-ELIGIBLE ACTIVITIESCapEx of Taxonomy non-eligibl

301、e activities19,051,820.0735.03%TOTAL54,394,546.15100%Proportion of CapEx/Total CapExTaxonomy-aligned per objectiveTaxonomy-eligible per objectiveCCM 0%2%CCA 0%0%WTR 0%0%PPC 0%63%CE0%0%BIO 0%0%Integrated Annual Report 202442IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Ta

302、xonomyOPEXFinancial year 2024Year 2024Substantial Contribution CriteriaDNSH criteria(Does Not Significantly Harm)Economic Activities(1)Code(2)OpEx(3)Proportion of OpEx 2023(4)Climate Change Mitigation(5)Climate Change Adaption(6)Water(7)Pollution(8)Circular Economy(9)Biodiversity(10)Climate Change M

303、itigation(11)Climate Change Adaption(12)Water(13)Pollution(14)Circular Economy(15)Biodiversity(16)Minimum Safeguards(17)Proportion of Taxonomy-aligned(A,1)or-eligible(A.2.)OpEx,2023(18)Category enabling activity(19)Category transitional activity(20)TextEUR%S,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S

304、,N,N/EL(b)(c)S,N,N/EL(b)(c)S,N,N/EL(b)(c)S/NS/NS/NS/NS/NS/NS/N%FTA.TAXONOMY-ELIGIBLE ACTIVITIESA.1.Environmentally sustainable activities(Taxonomy-aligned)OpEx of environmentally sustainable activities(Taxonomy-aligned)(A.1)00-0%Of which Enabling00-0%FOf which Transitional00-0%TA.2 Taxonomy-Eligible

305、 but not environmentally sustainable activities(not Taxonomy-aligned activities)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)EL;N/EL(f)1.2 Manufacture of medicinal products PPC 1.264,792,030.2881.81%N/ELN/ELN/ELELN/ELN/EL89.22%2.4 Remediation of contaminated sitesPPC 2.441,313.540.05%N/ELN/ELN/

306、ELELN/ELN/EL0.04%4.9 Transmission and distribution of electricityCCM 4.9102,794.930.13%ELN/ELN/ELN/ELN/ELN/EL0.13%4.30 High-efficiency co-generation of heat/cool and power from fossil gaseous fuelsCCM 4.30162,876.300.21%ELN/ELN/ELN/ELN/ELN/EL0.19%5.3 Construction,extension and operation of waste wat

307、er collection and treatment CCM 5.3213,061.560.27%ELN/ELN/ELN/ELN/ELN/EL0.11%6.5 Transport by motorbikes,passenger cars and light commercial vehiclesCCM 6.5184,205.910.23%ELN/ELN/ELN/ELN/ELN/EL0.30%6.6 Freight transport services by roadCCM 6.647,508.920.06%ELN/ELN/ELN/ELN/ELN/EL0.10%7.2 Renovation o

308、f existing buildingsCCM 7.223,000.000.03%ELN/ELN/ELN/ELN/ELN/EL*7.3 Installation,maintenance and repair of energy efficiency equipment CCM 7.32,655,850.943.35%ELN/ELN/ELN/ELN/ELN/EL2.82%7.5 Installation,maintenance and repair of instruments and devices for measuring,regulation and controlling energy

309、 performance of buildingsCCM 7.5233,559.740.29%ELN/ELN/ELN/ELN/ELN/EL0.29%8.1 Data processing,hosting and related activitiesCCM 8.1944,283.861.19%ELN/ELN/ELN/ELN/ELN/EL0.53%OpEx of Taxonomy-eligible but not environmen-tally sustainable activities(not Taxono-my-aligned activities)(A.2)69,400,485.9887

310、.62%0%0%0%81.81%0%0.05%93.84%A.OpEx of Taxonomy eligible activities(A.1+A.2)*169,400,485.9887.62%0%0%0%81.81%0%0.05%93.84%B.TAXONOMY-NON-ELIGIBLE ACTIVITIES OpEx of Taxonomy non-eligible activities9,802,119.4912.38%TOTAL79,202,605.47100%Proportion of OpEx/Total OpExTaxonomy-aligned per objectiveTaxo

311、nomy-eligible per objectiveCCM 0%6%CCA 0%0%WTR 0%0%PPC 0%81.86%CE0%0.00%BIO 0%0.00%Integrated Annual Report 202443IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Climate Change+Positive impact -Negative impact R Risk OO Own Operation SP Supply ChainClimate ChangeEnvironmen

312、tal governance at Grifols includes climate action.The company is committed to integrating sustainability into all operations and minimizing its environmental impact in alignment with global climate mitigation goals.As part of this commitment,Grifols incorporates climate risk management into its gove

313、rnance and strategic planning model,considering both physical risks(e.g.,extreme weather events)and transition risks such as regulatory and market shifts linked to climate policies.This approach enables the company to identify,assess and prioritize climate-related risks that could impact its operati

314、ons,products and services.More details:“Environmental Governance”section.Climate change is one of the worlds most urgent challenges.Global temperatures have risen in recent decades,and most prediction models indicate a significant increase in greenhouse gas(GHG)concentrations,leading to continued gl

315、obal warming in the coming years.Aware of the consequences of rising temperatures,Grifols has set clear targets to effectively reduce emissions;measures and manages its climate-related impacts,risks and opportunities;and implements a climate policy and strategy.Grifols climate strategy is driven by

316、its Board of Directors.Impacts,risks and opportunities E1 CLIMATE CHANGEMaterial IROs TypologyDescriptionCLIMATE CHANGE ADAPTATIONIncrease in extreme weather eventsR Physical Climate change is altering weather patterns worldwide,with the most relevant impacts for Grifols being extreme precipitation

317、and drought.Understanding current and potential physical climate risks is essential for managing the companys climate resilience.CLIMATE CHANGE MITIGATIONContribution to climate change from scope 1 and 2 GHG emissions-OO SPAs a global company,Grifols recognizes that its activities generate greenhous

318、e gas(GHG)emissions.The company is committed to advancing its climate action efforts by reducing its scope 1 and 2 emissions through proactive management.Contribution to climate change from scope 3 GHG emissions-OO SPScope 3 emissions account for approximately 80%of Grifols total emissions,with Cate

319、gory 1(purchased goods and services)being the largest contributor,followed by Category 4(transportation).In the coming years,Grifols aims to implement targeted actions to reduce these indirect emissions.Non-compliance with climate targets or legal requirementsRTransition Climate change and energy ef

320、ficiency regulations are becoming increasingly stringent.Companies may face significant consequences if they fail to meet climate targets or environmental laws.For this reason,Grifols dedicates substantial efforts to ensuring compliance with its climate targets.ENERGYNon-renewable energy consumption

321、-+OOGrifols continues to expand its use of renewable energy,which now accounts for 44.6%of its electricity consumption.The company prioritizes Power Purchase Agreements(PPAs)to increase the share of renewable energy in the market.Non-compliance with legal requirementsRClimate change and energy effic

322、iency regulations are becoming increasingly strict.Companies may face significant consequences if they fail to comply with these regulations.Insufficient energy supplyRThis refers to the risk of rising energy costs,production disruptions,and supply chain interruptions due to shortages of both renewa

323、ble and non-renewable energy sources or price volatility.Integrated Annual Report 202444IntroductionSustainability StatementSustainable growthAnnexesEnvironment l Climate ChangeClimate Risk and Opportunity AnalysisSince 2019,Grifols has regularly updated its climate risk map as part of its integrate

324、d approach to managing climate-related risks and opportunities.This framework helps the company determine whether a potential impact constitutes a material risk or opportunity.In 2024,within the framework of the companys resilience assessment,Grifols conducted a Climate Risk and Opportunity Analysis

325、 based on recommendations from the international scientific community and the general criteria established by key reporting frameworks such as the CSRD.The analysis included a stressed pessimistic scenario4(SSP5-8.5)from the IPCC to assess physical climate risks;a stressed optimistic scenario(NZS)fr

326、om the IEA to evaluate transition risks;and a strategic analysis aligned with TCFD recommendations,based on a 2C global warming scenario(SSP2-RCP-4.5).Analyzed dimensionROCC typologySelected scenariosShort termMedium termLong termAssets,business model(all economic activities)and supply chainPhysical

327、 risksSSP5-8.5(IPCC)SSP24.5(IPCC)2021-20402041-20602061-2100Transition risks and opportunitiesNZE*(IEA)203020502100Taxonomic activitiesPhysical risksSSP5-4.5(PCC)SSP24.5(PCC)2021-20402041-2060*The Net Zero Emissions by 2050 Scenario:A regulatory scenario that outlines a pathway for the global energy

328、 sector to achieve net-zero CO2 emissions by 2050,with advanced economies reaching net zero ahead of others.*For taxonomy-aligned economic activities exceeding 10 years,the assessment is conducted using the latest generation of climate projections,including,at a minimum,climate projection scenarios

329、covering 10 to 30 years.The potential financial impacts of each material risk and opportunity have also been estimated.For this process,27 potential climate-related risks and opportunities were evaluated across the companys entire value chain,including suppliers(upstream),Grifols own operations and

330、infrastructure,and the distribution and use of its products(downstream).Following this analysis,12 material risks and opportunities were identified:2 physical risks,6 transition risks and 4 opportunities.4.A climate scenario is a plausible description of how the climate might evolve in the future,ba

331、sed on assumptions about future greenhouse gas emissions and other factors that affect the climate.More details on the methodology and results:Risk and Opportunities Management Related to Climate Change.Integrated Annual Report 202445IntroductionSustainability StatementSustainable growthAnnexesEnvir

332、onment l Climate ChangeMATERIAL RISKS AND OPPORTUNITIES FOR GRIFOLSTypologyRisksDescriptionFinancial impactRisk management and mitigationPhysical(acute)Increase in frequency and intensity of heavy rainfall and floodingThe frequency and intensity of extreme precipitation and flooding are expected to

333、rise in many regions due to global warming.Grifols has facilities in some of these regions.Potential impacts include temporary production stoppages or a reduction in plasma collection due to donation center closures.This could lead to higher operational costs from relocating production to unaffected sites and lower revenue due to reduced plasma collection.Measures taken by Grifols to mitigate this